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Summary Background Omacetaxine mepesuccinate is indi-
cated in adults with chronic myeloid leukemia resistant and/or
intolerant to≥ 2 tyrosine kinase inhibitor treatments. This
phase I study assessed the disposition, elimination, and safety
of 14C-omacetaxine in patients with solid tumors. Methods
The study comprised a 7-days pharmacokinetic assessment
followed by a treatment period of≤ six 28-days cycles. A sin-
gle subcutaneous dose of 1.25 mg/m2 14C-omacetaxine was
administered to six patients. Blood, urine, and feces were col-
lected through 168 h or until radioactivity excretedwithin 24 h
was <1 % of the dose. Total radioactivity (TRA) was mea-
sured in all matrices and concentrations of omacetaxine, 4′-
desmethylhomoharr ingtonine (4 ′ -DMHHT), and
cephalotaxine were measured in plasma and urine. For each
treatment cycle, patients received 1.25 mg/m2 omacetaxine
twice daily for 7 days. Results Mean TRA recovered was
approximately 81 % of the dose, with approximately half of
the radioactivity recovered in feces and half in urine.
Approximately 20 % of the dose was excreted unchanged in
urine; cephalotaxine (0.4 % of dose) and 4′ DMHHT (9 %)
were also present. Plasma concentrations of TRAwere higher
than the sum of omacetaxine and known metabolites, suggest-
ing the presence of other 14C-omacetaxine-derived com-
pounds. Fatigue and anemia were common, consistent with
the known toxicity profile of omacetaxine. Conclusion Renal
and hepatic processes contribute to the elimination of 14C-
omacetaxine-derived radioactivity in cancer patients. In addi-
tion to omacetaxine and its known metabolites, other 14C-
omacetaxine-derived materials appear to be present in plasma
and urine. Omacetaxine was adequately tolerated, with no
new safety signals.
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Introduction
Omacetaxine mepesuccinate (henceforth referred to as
omacetaxine, Fig. 1) is a cephalotaxine ester that is approved
by the US Food and Drug Administration (FDA) as Synribo®
for the treatment of adult patients with chronic myeloid leu-
kemia (CML) with resistance and/or intolerance to two or
more tyrosine kinase inhibitors [1]. Omacetaxine is a semi-
synthetic product from the leaves of Cephalotaxus fortunei;
the chemical structure of omacetaxine is identical to that of the
natural product homoharringtonine, found in the bark of this
tree [2]. Omacetaxine is a protein synthesis inhibitor that has
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demonstrated activity in CML, acute promyelocytic leukemia,
acute myelogenous leukemia, and myelodysplastic syndrome
[1, 3–11]. Omacetaxine’s activity is independent of direct
binding to breakpoint cluster region-abelson (Bcr-Abl) tyro-
sine kinase. Instead, it binds to the A-side cleft of ribosomes,
thus reducing levels of multiple short-lived oncoproteins in-
volved in cell survival and proliferation pathways [12, 13].
For patients with CML, the induction dose is 1.25 mg/m2
administered by subcutaneous injection twice daily for 14 days
every 28 days; the maintenance dosage and route are the same
as for induction, with omacetaxine administered for 7 days of
a 28-days cycle [14].
To date, little is known about the metabolism, disposition,
and elimination of omacetaxine. In a previous in vivo metab-
olite study in mice, 4′-desmethylhomoharringtonine (4′-
DMHHT, Fig. 1) was the primary metabolite identified [15].
In mice, conversion occurred quickly (within 5 min of intra-
venous administration), and in vitro assessments suggested
that the process of hydrolysis was mediated primarily by plas-
ma esterase [15]. The formation of 4′-DMHHT was also
shown to occur when omacetaxine was incubated with liver
microsomes isolated from rats and rabbits [16]. Cephalotaxine
(Fig. 1) is a minor, inactive metabolite of omacetaxine [15]. In
a previous phase I study, 4′-DMHHT and cephalotaxine con-
centrations were determined in plasma and urine;
cephalotaxine was undetectable in most patients, and the
steady-state area under the curve (AUC) estimate for 4′-
DMHHT was approximately 13 % of that for omacetaxine
[17].
The primary objective of the present study was to charac-
terize the disposition and elimination pathway of 14C-




This was a phase I, open-label, single-institution study con-
ducted in accordance with International Conference on
Harmonisation guidelines for Good Clinical Practice, the US
Code of Federal Regulations, and the European Union
Directive. The protocol was approved by The Netherlands
Cancer Institute Independent Ethics Committee. All patients
provided written, informed consent at the time of screening.
The study was divided into two assessment periods; period
A comprised 7 days during which the mass balance and phar-
macokinetics of 14C-omacetaxine were investigated, and pe-
riod B was an extended-use period of 28-days cycles with
nonlabeled omacetaxine. Safety was assessed during both
periods.
Patients
Eligible patients were at least 18 years of age and had histo-
logically or cytologically confirmed relapsed and/or refractory
hematologic malignancies or advanced solid tumors consid-
ered unresponsive or poorly responsive to standard care. Only
patients with advanced solid tumors participated; none had
hematologic malignancies. Other eligibility criteria included
World Health Organization performance status of 2 or lower;
estimated life expectancy of at least 3 months; QTc less than
450 msec; normal hepatic function (defined as≤upper limit of
the normal range [ULN] for aspartate aminotransferase [AST]
and total bilirubin, or mild hepatic dysfunction (defined as
bilirubin ≤ 1.5 times the ULN and AST greater than the
ULN, or bilirubin>1.0 to 1.5 times the ULN and any AST);
and adequate renal function (creatinine clearance≥60 mL/
min). Patients with nonhematologic malignancies were re-
quired to have absolute neutrophil counts of at least 1000
cells/mm3, platelet counts of at least 100,000 cells/mm3, and
hemoglobin values of at least 8 g/dL. Male patients were re-
quired to be surgically sterile or currently using an approved
method of birth control for at least 90 days after drug discon-
tinuation, and female patients were required to be surgically
sterile or 2 years postmenopausal.
Patients were excluded if they had received mitomycin C
w i t h i n 42 day s ; c h emo t h e r a py, r a d i o t h e r a py,
radioimmunotherapy, or immunotherapy within 28 days; or
hematopoietic growth factors within 14 days prior to the first
dose or if they had not recovered from adverse events (AEs)
caused by previously administered agents. Other reasons for
exclusion included pregnancy or breastfeeding; New York
Fig. 1 Chemical structure of 14C-
omacetaxine and its known
metabolites 4′-DMHHT and
cephalotaxine. The asterisk in the
14C-omacetaxine structure
indicates the position of the 14C-
label
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Heart Association Class III or IV heart disease; myocardial
infarction; solid tumor with symptomatic central nervous sys-
temmetastases; systemic infection ormedical/psychiatric con-
dition; other treatments for hematologic or nonhematologic
malignancy; known hypersensitivity to omacetaxine, manni-
tol, or other components of the study drug; previous treatment
with omacetaxine; or significant constipation or obstruction of
the urinary tract.
Study treatment
Labeled 14C-omacetaxine (chemical purity 99 %, radiochem-
ical purity 98 %, chiral purity 100 %) was prepared by Selcia
Limited (Ongar, Essex, UK) and supplied by Teva
Pharmaceuticals (North Wales, PA, USA). Drug product for
period A was manufactured for each patient by PRA Early
Development Services (Zuidlaren, The Netherlands) and
contained a mixture of 14C-omacetaxine and nonlabeled
omacetaxine in a 1-mL plastic syringe, with approximately
95 μCi of 14C. The specific activity and concentration of the
mixture were approximately 135 μCi/mL and 3 mg/mL, re-
spectively. Therefore, both the 14C-labeled and nonlabeled
dose were adjusted based on the body surface area (BSA) of
each individual patient. Nonlabeled omacetaxine was provid-
ed in a lyophilized vial containing 3.5 mg of omacetaxine and
10 mg of mannitol in an 8-mL clear glass vial by Teva
Pharmaceuticals.
On day 1 of period A, each patient received a single sub-
cutaneous dose of 14C-omacetaxine 1.25 mg/m2 at the study
center. The first 72 h of assessment in period Awere conduct-
ed on an inpatient basis. Blood samples and excreta were
collected for up to 168 h after administration. If necessary,
excreta collections were continued on an outpatient basis until
total radioactivity (TRA) excreted in the urine and feces col-
lections in a 24-h period were less than 1 % of the adminis-
tered dose. The TRA measurements for each patient were
adjusted based on the specific activity of the individual dose.
During period A, patients received a high-fiber diet and ade-
quate fluid intake (≥2 L/day) to expedite intestinal transit and
reduce the potential for retention of radioactivity.
Period B started on day 4 of period A (following the 72-h
pharmacokinetic sample collection). During period B, patients
were treated with nonlabeled omacetaxine 1.25 mg/m2 subcu-
taneously twice daily for 7 days (solid tumors) or 14 days
(hematologic malignancies) of each 28-days cycle for a max-
imum of six cycles. If this dose was not tolerated, it could be
started at or lowered to 1.0 mg/m2, as allowed in the protocol,
and the number of dosing days modified.
Sample collection
For pharmacokinetics analyses, blood samples of 6 mL were
collected in K2EDTA tubes prior to the injection and at 15, 30,
45, and 60 min and 2, 4, 8, 12, 24, 32, 48, and 72 h after 14C-
omacetaxine injection, and 4-mL samples were collected 96,
120, 144, and 168 h after injection. The tubes were placed in
ice water after collection and centrifuged (1800 g, 4 °C,
15 min) within 5 min. Plasma was isolated and aliquoted for
TRA measurements; samples collected through 72 h were
stabilized with 5 % of a 0.4 % ethanolic paraoxon solution
for bioanalysis. Paraoxon has been shown to be an effective
inhibitor of omacetaxine hydrolysis as mediated by plasma
esterases [18]. In addition, 1 mL of whole blood was collected
30 min and 8, 72, and 168 h after injection and optionally
twice every week thereafter for TRA measurements.
Urine samples were collected before 14C-omacetaxine in-
jection and then as voided through 168 h after injection, until
the total excreted radioactivity per day (urine and feces com-
bined) was less than 1 % of the total administered dose
(whichever was earlier) or through more than 168 h if TRA
represented at least 1 % of the radiochemical dose in the 144-
to 168-h collection period. Each urine sample was aliquoted
for measurement of TRA, and additional aliquots for samples
collected through 72 h were prepared for bioanalysis.
Fecal samples were collected per portion, before 14C-
omacetaxine injection and then as voided through 168 h after
injection, until the total excreted radioactivity per day was less
than 1 % of the total administered dose (whichever was earli-
er), or longer if TRA represented at least 1 % of the radio-
chemical dose in the 144- to 168-h collection of feces. The
fecal portions were weighed, stored refrigerated, and homog-
enized after addition of water (1:3w/v). The homogenized
fecal samples were aliquoted for measurement of TRA.
Plasma aliquots, urine aliquots, whole blood aliquots, and
fecal homogenate aliquots were stored within a range between
−70 and −90 °C. The plasma, urine, and fecal samples collect-
ed were also used for metabolic profiling and identification.
The results of these analyses are reported elsewhere [18].
Total radioactivity analysis
The TRA in plasma, whole blood, urine, and feces was deter-
mined by liquid scintillation counting. Plasma (0.2 mL) and
urine (1 mL) samples were mixed directly with 10 mL liquid
scintillation cocktail (Ultima GoldTM, Perkin Elmer Inc.,
Waltham, MA, USA). To the whole blood samples (0.2 mL),
1 mL Solvable (Perkin Elmer Inc.), 0.1 mL 0.1 M EDTA, and
0.5 mL 30 % hydrogen peroxide were added to dissolve and
decolorize the samples. Feces homogenates (0.2 mL) were
first dissolved and decolorized using 1 mL Solvable (Perkin
Elmer Inc.), 1 mL isopropanol, and 0.4 mL 30 % hydrogen
peroxide. The decolorization reaction was started by warming
the samples in a shaking water bath of approximately 43 °C,
after which the samples were placed in a dark cool place for at
least 1 h before liquid scintillation cocktail (10 mL) was
added. Samples were counted on a Tri-Carb® 2800TR liquid
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scintillation counter (Perkin Elmer Inc.). Quench correction
was applied with a calibration curve of quenched radioactive
reference standards. Samples were counted to a sigma 2
counting error of 5 % or for 60 min at most. The lower limit
of quantitation (LLOQ) was approximated to be 1.2 to 1.4 ng-
eqv/g using the counting error as described previously [18,
19].
Analysis of omacetaxine, 4′-DMHHT, and cephalotaxine
Plasma and urine samples collected through 72 h after
injection were additionally analyzed using validated liq-
uid chromatography-tandem mass spectrometry assays,
described elsewhere [20], to quantify unchanged
omacetaxine and the metabolites 4 ′-DMHHT and
cephalotaxine (Fig. 1).
Plasma samples were prepared using protein precipitation
with acetonitrile-methanol (80:20, v/v), and urine samples
were prepared using solid-phase extraction. Both plasma and
urine samples were separated on an XBridge BEH Phenyl
column (50×2.1 mm internal diameter, particle size 5 μm;
Waters, Etten-Leur, The Netherlands). Detection was per-
formed with a QTrap 5500 MS/MS (Sciex, Thornhill, ON,
Canada) equipped with a turbo ion spray interface, operating
in positive mode and configured in multiple-reaction monitor-
ing. The validated calibration range of omacetaxine, 4′-
DMHHT, and cephalotaxine in plasma was 0.1 to 100 ng/
mL; in urine it was 0.1 to 50 ng/mL. Thus, the LLOQ was
defined as 0.10 ng/mL for omacetaxine and its metabolites.
Quality control samples were prepared and analyzed together
with the study samples. Acceptance criteria for bioanalytical
data during routine sample analysis, as described in the FDA
and European Medicines Agency guidelines, were applied
[21, 22].
Pharmacokinetic analysis
The pharmacokinetic analysis set included those patients
for whom at least one pharmacokinetic parameter could
be calculated postbaseline. Pharmacokinetic parameters
were estimated using noncompartmental analysis with
Phoenix™ WinNonl in® (vers ion 6.3 , Phars ight
Corporation, Mountain View, CA, USA). The following
pharmacokinet ic parameters were est imated for
omacetaxine, 4′-DMHHT, cephalotaxine, and TRA when
possible: maximum observed plasma concentration
(Cmax), time to Cmax (tmax), terminal elimination half-life
(t1/2), and area under the plasma concentration-time curve
(AUC). For omacetaxine, the apparent plasma clearance
(CL/F), apparent volume of distribution (Vz/F), renal
clearance (CLR), and metabolite-to-parent AUC ratios
were also determined.
Safety assessments
The safety of omacetaxine was assessed by grading AEs ac-
cording to National Cancer Institute Common Terminology
Criteria for AEs (NCI CTCAE) version 4.0, clinical laboratory
test results (hematology, serum chemistry, and/or urinalysis),
vital signs and body weight measurements, electrocardiogra-
phy and physical examination results, and concomitant med-
ication usage.
Statistical analysis
No formal statistical analysis was applied in this study; de-
scriptive statistics were used when appropriate.
Results
Patients
Six patients with advanced solid tumors (three with colorectal,
two with lung, and one with ovarian) were enrolled and com-
pleted period A of the study (Table 1). One patient with colo-
rectal cancer was withdrawn from the study at the end of
period A because of a grade 2 serious AE of constipation
(not related to study treatment). Five patients continued into
period B. None of the patients completed six cycles of
omacetaxine; three patients completed one cycle, and two
completed two cycles. Reasons for early discontinuation were
lack of efficacy (three patients), patient decision (one patient),
and general deterioration (one patient).
All six patients were white; five were female and one was
male, with a mean age of 56.7 years (range 43–69), a mean
weight of 81.9 kg (range 70.6–90.2), a mean height of 174 cm
(range 170–184), and a mean body surface area of 2.0 m2
(range 1.8–2.1). All patients completed period A and were
therefore evaluable for safety and pharmacokinetic analysis.
Pharmacokinetics
Plasma concentration-time curves of TRA, omacetaxine, and
4′-DMHHT through 72 h after the administration of 14C-
omacetaxine are presented in Fig. 2. A summary of pharma-
cokinetic parameters is displayed in Table 2.
After administration of a single dose of 14C-omacetaxine,
tmax of TRA and omacetaxine were recorded at approximately
0.5 h. After reaching peak levels, the mean plasma concentra-
tions of omacetaxine declined in a biphasic manner that was
characterized by an initial rapid phase followed by a slower
terminal phase with a mean half-life of 14.6 h (Fig. 2).
Observed plasma concentrations for 4′-DMHHT were sub-
stantially lower than for omacetaxine. After reaching peak
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levels, 4′-DMHHT concentrations declined in a monophasic
manner.
The metabolite cephalotaxine was quantifiable in only one
plasma sample from a single patient at 15 min after adminis-
tration of 14C-omacetaxine.
During the first hour postdose, TRA concentrations were
comparable to those for omacetaxine (Fig. 2). Subsequently,
the TRA and omacetaxine concentration-time profiles began
to diverge but declined in parallel. In a comparison of the
concentrat ions of omacetaxine, 4 ′-DMHHT, and
cephalotaxine to TRA concentrations within the first hour
postdose, more than 90 % of the TRA was accounted for by
the sum of the three compounds (Fig. 3). At subsequent time
points through 32 h postdose, these three compounds com-
prised approximately 70 to 80 % of the TRA.
At 0.5 h and 8 h postdose, the plasma-to-whole blood con-
centration ratios of TRAwere 1.40 and 1.39, respectively. The
ratios were not calculable for samples collected at 72 or 168 h
postdose, because TRA concentrations in both matrices at
those time points were below the limit of quantitation.
Excretion balance
Table 3 and Figs. 4 and 5 summarize the mean cumulative
excretion in urine of TRA, unchanged omacetaxine, 4′-
DMHHT, and cephalotaxine during the first 72 h and themean
cumulative urinary, fecal, and total recovery of TRA during
168 h after administration of a single subcutaneous dose of
14C-omacetaxine.
Urinary recovery of omacetaxine and 4′-DMHHTwas 20.7
and 9.2 %, respectively, of the administrated dose, and recov-
ery of cephalotaxine was low (0.4 %) in the first 72 h
(Table 3). Excretion was moderately slow for all three com-
pounds, with the bulk of urinary recovery occurring within
36 h postdose (Fig. 4).
Over the 168 h of sample collection, the mean cumulative
urinary recovery of TRA was 36.9 % of the administered
radiolabeled dose. Most of this TRA (35.2 %) was excreted in
the first 72 h postdose. The recovery of TRA in 72 hwas slightly
higher than the sum of the recoveries of omacetaxine and its two
metabolites over this same period (35.2 % versus 30.3 %).
Table 1 Baseline patient characteristics (N= 6)
Characteristic Value







Not Hispanic or Latino 6 (100)
Median weight, kg (range) 85.1 (70.6–90.2)
Median height, cm (range) 171 (165–184)
Median body surface area, m2 (range) 2.0 (1.8–2.1)
Median time since cancer diagnosis, months (range) 26.6 (18.1–42.0)




Received prior cancer drug therapy, n (%) 6 (100)
ECOG performance status, n (%)
1 4 (67)
2 2 (33)
ECOG, Eastern Cooperative Oncology Group
Fig. 2 Mean (+ standard
deviation) log-linear plasma
concentration-time curves of total
radioactivity (TRA), omacetaxine
and 4′-DMHHT (DMHHT) in
plasma (N= 6)
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Substantial fecal excretion of TRA was also observed in
these patients. After 168 h, the mean total recovery of TRA
in feces was 39.3 % of the administered radiolabeled dose. In
contrast to urinary recovery, in which the majority of the TRA
was excreted during the first day, fecal excretion occurred
much more slowly (Fig. 5).
The mean total recovery in excreta at 168 h after adminis-
tration represented 76.2 % of the administered radiolabeled
dose; however, small amounts of radioactivity were still pres-
ent in the last scheduled collection of excreta of some patients.
Therefore, urine and/or feces collections continued beyond
168 h for all but one patient, whose collections ended at
144 h because less than 1 % of the administered radioactivity
had been excreted in both matrices on that day. The mean total
recovery in excreta after the total collection period (range,
144–312 h postdose for individual patients) was 80.5 % of
the administered dose.
Safety
Each of the six enrolled patients experienced at least one AE
(100 %). A summary of treatment-emergent AEs is presented
in Table 4; the most frequently reported were fatigue (83 %),
anemia (50 %), nausea (50 %), and back pain (50 %). The
majority of AEs were grade 1 or 2 in severity (NCI CTCAE
v4.0). The most common grade 3 AE was anemia (33 %).
Table 2 Plasma pharmacokinetic
parameters for total radioactivity,
omacetaxine, and its metabolite
4′-DMHHT following a single
subcutaneous dose of 1.25 mg/m2
















Mean 30.9 0.6c 262 292 11.3 ND ND ND
SD 6.1 0.3–1.0c 127 134 2.5 ND ND ND
Omacetaxine
Mean 28.6 0.48c 180 188 14.6 268 14.4 ND
SD 6.5 0.3–0.5c 75.4 79.9 5.5 59.3 6.2 ND
4′-DMHHT
Mean 3.5 3.98c 45.3 49.6 10.7 ND ND 0.27
SD 1.3 0.2–8.1c 33.0 34.1 2.9 ND ND 0.14
AUC0-t area under the plasma concentration-time curve from time zero to time of the last quantifiable concentra-
tion,, AUC0-inf area under the plasma concentration-time curve from time zero to infinity, CL/F total plasma
clearance, Cmax maximum observed plasma concentration, M:P metabolite-parent, NA not applicable, ND not
determined, SD standard deviation, t1/2 terminal elimination half-life, tmax time to maximum observed plasma
concentration, TRA total radioactivity, Vz/F apparent volume of distribution
a Units are ng-eqv/g for TRA
bUnits are ng-eqv h/g for TRA
cMedian/range values presented
Fig. 3 Mean (+standard
deviation) log-linear plasma




(CT) in plasma (N= 6)
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Other grade 3 AEs experienced by one patient each were
abdominal pain, fatigue, hypophosphatemia, and dyspnea.
Thrombocytopenia was the most common grade 4 AE; grade
4 neutropenia was experienced by one patient. Three patients
experienced a total of 4 serious AEs that included grade 2
constipation, grade 4 thrombocytopenia, grade 3 anemia,
and grade 3 dyspnea.
No deaths occurred in this study. One patient with co-
lorectal cancer experienced grade 2 constipation on day 2
of the study that necessitated hospitalization and was
resolved on day 7. This patient withdrew from the study
on day 8 because of a second serious AE of constipation.
The lowest recovery of TRA was obtained in this patient
(68.7 % versus 70.6 to 89.9 % for the other five patients),
but the pattern of excretion between urine and feces was
similar. This event was reported as recovered/resolved
with sequelae on day 15, but the patient continued to
experience further grade 1 constipation. None of these
events were considered to be related to omacetaxine.
Assessment of clinical laboratory parameters revealed
grade 1 serum chemistry changes for alkaline phospha-
tase, calcium, glucose, potassium, and aspartate
aminotransferase/alanine aminotransferase. One patient
experienced a grade 3 serum glucose increase that was
related to an underlying medical condition and unrelated
to study treatment. Laboratory hematologic findings in-
cluded grade 4 neutropenia, grade 3/4 leucopenia, and
grade 3/4 thrombocytopenia in three patients each and
grade 3 lymphopenia in two patients. All grade 3/4 hema-
tologic findings were not serious and were considered
related to study drug. One patient experienced grade 3
anemia and grade 4 thrombocytopenia reported as a seri-
ous AE. The hematologic findings were consistent with
the known side-effect profile of omacetaxine and with
findings in a patient population heavily pretreated with
chemotherapy.
No significant changes in electrocardiography were attrib-
uted to omacetaxine, and no QTc prolongation was evident.
One patient, with a history of atrial fibrillation, experienced
nonserious grade 2 atrial fibrillation on day 1 was treated with
an increased dose of digoxin. The atrial fibrillation was con-
sidered not related to the study drug and resolved on day 3.
Changes in performance status were based on progression of
Table 3 Recovery of omacetaxine and metabolites in urine after 72 h,
and of total radioactivity in excreta after 168 h and after the total recovery
period (range, 144–312 h postdose) (N= 6)
Mean [Min, Max], % SD, %
Cumulative % recovered in urine up to 72 h
Omacetaxine 20.7 [15.3, 32.1] 6.0
4′-DMHHT 9.2 [5.5, 13.1] 2.6
Cephalotaxine 0.4 [0.2, 0.6] 0.2
Total 30.3 [22.8, 42.9] 6.7
TRA 35.2 [25.9, 42.9] 6.4
Cumulative % TRA recovered up to 168 h
Urine 36.9 [26.8, 45.8] 7.6
Feces 39.3 [20.8, 57.2] 16.6
Total 76.2 [66.3, 89.3] 9.7
Cumulative % TRA recovery after total collection period
Urine 37.0 [26.8, 45.8] 7.7
Feces 43.5 [24.8, 57.5] 13.7
Total 80.5 [68.7, 89.9] 8.7
Max maximum, Min minimum, SD standard deviation, TRA total
radioactivity
Fig. 4 Mean (+standard
deviation) cumulative urinary




(CT) up to 72 h after a subcuta-
neous injection (1.25 mg/m2) of
14C-omacetaxine (N = 6)
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disease, and physical findings were otherwise those expected
for this patient population.
Discussion and conclusions
This study investigated the disposition and elimination of 14C-
omacetaxine in adult patients with solid tumors following a
single subcutaneous dose. After administration, the observed
pharmacokinetic profiles of omacetaxine and 4′-DMHHT
were consistent with results from a previous study in patients
with cancer [17]. The high apparent volume of distribution
suggests that omacetaxine is distributed extensively into the
tissues; this is consistent with previous reports in which the
drug was administered either as a subcutaneous injection or an
intravenous infusion [17, 23]. The longer half-life and larger
systemic exposure (AUC) to omacetaxine and 4′-DMHHT
observed in this study compared with the previous study are
attributed to the longer sampling period used (72 versus 12 h).
The summed concentrations of omacetaxine and its metab-
olites accounted for more than 90 % of the TRA concentra-
tions through the first hour after administration. Subsequently,
the concentration profiles diverged, and, at 32 h postdose, the
three compounds accounted for approximately 70 % of the
TRA. These results suggest that other 14C-omacetaxine-de-
rived materials are present in plasma at later hours postdose.
The ratio of plasma to blood TRA concentrations were
close to unity over the two time points assessed, suggesting
that there was no preferential association of 14C-omacetaxine-
derived radioactivity with cellular components of the blood.
The mean total recovery of TRA in excreta during the
collection period of up to 312 h was 80.5 %. The large appar-
ent volume of distribution and associated potential tissue bind-
ing might explain why higher excretion recovery was not
achieved. This is in line with the radioactivity recovery in
previous mass balance studies of chemotherapy agents [24].
Samples were collected until excretion declined to less than
1 % of the administered dose over 24 h. A higher recovery
could have been obtained if the collection time had been ex-
tended, but the added value of additional excretion data was
considered limited.
Half of the radioactivity was excreted in urine and half in
feces, which suggests that both hepatic and renal processes
contribute to the elimination of omacetaxine. The elimination
of omacetaxine, 4′-DMHHT, and cephalotaxine in urine was
moderately slow, with the majority excreted within 36 h
postdose. The excretion data reported here for omacetaxine,
4′-DMHHT, and cephalotaxine within the first 24 h after ad-
ministration correspond to results reported previously by
Nemunaitis et al., who found urinary excretion of
omacetaxine, 4′-DMHHT, and cephalotaxine to be 12 to
15 %, 4 to 5 %, and 0.07 %, respectively [17]. The recovery
of TRA in 72 h was slightly higher than the sum of the recov-
eries of omacetaxine and its two metabolites over this same
period (35.2 % versus 30.3 %), suggesting that other 14C-
omacetaxine-derived materials may be present. Fecal excre-
tion occurred much more slowly than did excretion in urine
and showed larger deviations, likely related to variation in the
amount of fecal excretion per patient. Metabolites of
omacetaxine have not been extensively characterized in pre-
clinical studies, but the amount of radioactivity and un-
changed omacetaxine in urine and feces suggests that the pro-
cesses involved in the elimination of omacetaxine are similar
in humans, dogs, and mice [15, 23, 25].
Treatment with omacetaxine in this heavily pretreated pa-
tient population with advanced solid tumors was tolerated,
with an AE profile consistent with that known for
omacetaxine and those related to the underlying malignancies
Fig. 5 Mean (+standard
deviation) cumulative recovery of
total radioactivity in urine, feces,
and total excreta during 168 h
after a subcutaneous injection
(1.25 mg/m2) of 14C-omacetaxine
(N = 6)
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of these patients. Fatigue, anemia, thrombocytopenia, neutro-
penia, diarrhea, and nausea were the most common treatment-
related AEs reported and were expected. There were no clin-
ically meaningful changes from baseline in serum chemistries,
and the hematologic parameter changes were consistent with
the known side-effect profile of omacetaxine. Therefore, no
new safety signals were observed during the course of this
study.
In conclusion, results from this study suggest that both
renal and hepatic processes contribute to the elimination of
14C-omacetaxine-derived radioactivity in patients with solid
tumors. In addition to omacetaxine and its known metabolites,
other 14C-omacetaxine-derived materials appear to be present
in both plasma and urine. Omacetaxine was adequately toler-
ated by these patients with end-stage cancer, and no new safe-
ty signals were observed.
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Table 4 Treatment-emergent
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Nausea 3 (50) 0 0 0
Vomiting 1 (17) 0 0 0
General disorders and administration site conditions 0 4 (67) 1 (17) 0
Fatigue 0 4 (67) 1 (17) 0
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AE adverse event, MedDRA Medical Dictionary for Regulatory Activities
If a patient reported an AE more than once, the greatest severity is presented for that AE. Patients were counted
only once in each preferred term category and only once in each system organ class category, at the greatest
severity for each
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